Published in Front Physiol on July 13, 2012
A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology (2013) 1.72
Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.55
Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol (2013) 1.06
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol (2013) 1.03
Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol (2014) 1.00
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother (2014) 0.97
Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int (2014) 0.90
Mast cells density positive to tryptase correlates with angiogenesis in pancreatic ductal adenocarcinoma patients having undergone surgery. Gastroenterol Res Pract (2014) 0.88
Serglycin: at the crossroad of inflammation and malignancy. Front Oncol (2014) 0.87
Contribution of bone marrow derived cells to the pancreatic tumor microenvironment. Front Physiol (2013) 0.85
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer (2014) 0.85
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology (2014) 0.84
Altered sphingolipid metabolism in patients with metastatic pancreatic cancer. Biomolecules (2013) 0.82
Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front Physiol (2013) 0.82
PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget (2016) 0.79
Identification and characterization of the gene expression profiles for protein coding and non-coding RNAs of pancreatic ductal adenocarcinomas. Oncotarget (2015) 0.78
Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol (2016) 0.77
Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One (2016) 0.76
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer. Oncoimmunology (2015) 0.75
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Pancreatology (2016) 0.75
Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice. J Cancer Sci Ther (2013) 0.75
Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model. PLoS One (2017) 0.75
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Pancreas (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Inflammation and cancer. Nature (2002) 53.78
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Functional diversity of helper T lymphocytes. Nature (1996) 18.09
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med (1993) 7.67
Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 6.96
Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science (2010) 6.06
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol (2005) 4.92
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Stromal biology and therapy in pancreatic cancer. Gut (2010) 3.80
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother (2008) 3.32
Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg (2008) 3.21
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Co-evolution of tumor cells and their microenvironment. Trends Genet (2008) 3.08
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 2.97
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest (2010) 2.90
Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res (2008) 2.66
Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res (2009) 2.61
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg (2008) 2.38
Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg (2010) 2.16
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Pancreatic cancer-associated stroma production. Am J Surg (2007) 2.12
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Mast cells and angiogenesis. APMIS (2002) 1.88
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol (2004) 1.88
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res (2008) 1.75
Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 1.75
Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol (2012) 1.70
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res (2008) 1.61
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther (2011) 1.61
Neutrophils: Cinderella of innate immune system. Int Immunopharmacol (2010) 1.59
Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res (2004) 1.54
Regulation of mast cell responses in health and disease. Crit Rev Immunol (2011) 1.50
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
Molecular mechanisms of treg-mediated T cell suppression. Front Immunol (2012) 1.41
The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev (2011) 1.29
Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol (2002) 1.28
Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 1.26
CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology (2010) 1.26
Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother (2009) 1.23
Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol (2008) 1.23
Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res (2012) 1.23
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol (2008) 1.18
Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol (2011) 1.14
Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS One (2011) 1.13
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery (2008) 1.11
Targeting regulatory T cells. Target Oncol (2012) 1.10
Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2010) 1.04
Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol (2011) 1.03
Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery (2010) 1.01
Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J (2005) 0.98
Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion. J Surg Res (2005) 0.97
Mast cells, angiogenesis and cancer. Adv Exp Med Biol (2011) 0.97
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer Immunol Immunother (2009) 0.89
Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev Res (Phila) (2010) 0.89
Hereditary pancreatitis and secondary screening for early pancreatic cancer. Rocz Akad Med Bialymst (2005) 0.86
CD4+ T helper 2 cells--microbial triggers, differentiation requirements and effector functions. Immunology (2011) 0.86
Biology and management of pancreatic cancer. Gut (2007) 2.53
Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol (2003) 1.83
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer (2004) 1.68
Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology (2005) 1.61
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer (2011) 1.38
Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One (2012) 1.36
Dual-color proteomic profiling of complex samples with a microarray of 810 cancer-related antibodies. Mol Cell Proteomics (2010) 1.21
High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res (2005) 1.18
Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics (2003) 1.14
A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics (2009) 1.04
Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res (2009) 1.02
Pancreatic cancer susceptibility loci and their role in survival. PLoS One (2011) 0.98
Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut (2010) 0.98
Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis (2010) 0.96
Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Dig Liver Dis (2012) 0.95
The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics (2007) 0.94
MCP-1 but not CINC synthesis is increased in rat pancreatic acini in response to cerulein hyperstimulation. Am J Physiol Gastrointest Liver Physiol (2002) 0.92
Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology (2009) 0.90
cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC. Biochim Biophys Acta (2013) 0.90
Proteomic technologies and their application to pancreatic cancer. Expert Rev Proteomics (2004) 0.88
New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol (2008) 0.87
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med (2004) 0.87
Biomarkers for early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol (2014) 0.86
Genetics and prevention of pancreatic cancer. Cancer Control (2004) 0.85
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int J Cancer (2013) 0.84
Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Cancer Epidemiol Biomarkers Prev (2012) 0.81
Somatic mutations in exocrine pancreatic tumors: association with patient survival. PLoS One (2013) 0.81
Analysis of serum proteins by LC-MS/MS. Methods Mol Biol (2010) 0.79
Tetracycline-inducible protein expression in pancreatic cancer cells: effects of CapG overexpression. World J Gastroenterol (2011) 0.76
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg (2016) 0.75
The pancreatic cancer proteome - recent advances and future promise. Proteomics Clin Appl (2007) 0.75
Pancreatic mass in a young CFTR carrier with a heterozygous p.R117H CFTR gene mutation and homozygous 7T. Pancreas (2015) 0.75
Trials of gene therapy for pancreatic carcinoma. Curr Gastroenterol Rep (2005) 0.75
Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. Expert Rev Gastroenterol Hepatol (2012) 0.75